Table 1.
Characteristics of the study population overall and according to the mean monthly percentage change in Epoetin alfa (EPO) dose over the sub-11 perioda
| Variable | Overall (n = 6133; mean %) | Mean Monthly Change in EPO Dose (%)b
|
||||
|---|---|---|---|---|---|---|
| < 0 (n = 746) | 0 to 12.5 (n = 1432) | >12.5 to 25 (n = 1491) | >25 to 37.5 (n = 981) | >37.5 (n = 1483) | ||
| Age (yr) | 59.3 (15) | 56.2 (15.0) | 58.8 (15.0) | 59.8 (14.7) | 60.1 (14.8) | 60.5 (14.7) |
| Female gender | 52.0 | 51.1 | 53.8 | 51.8 | 51.5 | 51.1 |
| Race | ||||||
| black | 47.7 | 48.8 | 48.7 | 48.7 | 46.9 | 45.7 |
| white | 43.6 | 41.7 | 42.3 | 44.0 | 46.4 | 44.5 |
| other | 8.7 | 9.5 | 10.1% | 7.3 | 6.7 | 9.8 |
| Body mass index (kg/m2) | 27.5 (8.5) | 28.3 (9.9) | 27.9 (8.5) | 27.7 (8.7) | 27.4 (7.9) | 26.7 (7.8) |
| Diabetes as primary cause of ESRD | 35.2 | 33.8 | 35.1 | 35.4 | 36.3 | 32.2 |
| Initiated dialysis within 1 yr of entry period | 16.2 | 16.9 | 16.8 | 17.8 | 17.5 | 13.0 |
| Months on dialysis | 45.1 (42.6) | 45.5 (43.1) | 44.1 (39.8) | 45.9 (45.6) | 43.4 (41.9) | 46.2 (42.4) |
| Vascular access type at end of month 6 | ||||||
| catheter | 28.9 | 30.4 | 28.7 | 28.9 | 30.9 | 27.2 |
| fistula | 24.2 | 22.0 | 22.0 | 25.1 | 25.2 | 25.8 |
| graft | 46.9 | 47.6 | 49.3 | 46.0 | 43.9 | 47.0 |
| Mean albumin (g/dl) | ||||||
| months 1 to 3 | 3.8 (0.4) | 3.7 (0.4) | 3.7 (0.4) | 3.8 (0.4) | 3.8 (0.3) | 3.9 (0.3) |
| months 4 to 6 | 3.7 (0.4) | 3.7 (0.4) | 3.7 (0.4) | 3.7 (0.4) | 3.8 (0.4) | 3.8 (0.4) |
| Mean ferritin (ng/ml) | ||||||
| months 1 to 3 | 585 (469) | 587 (680) | 544 (423) | 573 (438) | 582 (433) | 638 (427) |
| months 4 to 6 | 663 (516) | 628 (625) | 617 (547) | 643 (468) | 657 (464) | 749 (494) |
| Mean TSAT (%) | ||||||
| months 1 to 3 | 28.2 (11.8) | 26.5 (13.3) | 26.2 (11.1) | 28.4 (11.8) | 28.5 (11.3) | 30.4 (11.5) |
| months 4 to 6 | 25.8 (11.5) | 25.0 (12.6) | 24.3 (11.3) | 25.8 (11.4) | 26.0 (11.2) | 27.5 (11.2) |
| Mean iron dose (mg) | ||||||
| months 1 to 3 | 97.9 (53.2) | 102 (61.8) | 98.1 (53.2) | 96.1 (48.6) | 96.0 (50.7) | 99.2 (54.9) |
| months 4 to 6 | 99.1 (53.2) | 106 (73.7) | 99.1 (42.7) | 97.0 (42.1) | 97.2 (39.2) | 99.3 (67.1) |
| Mean hemoglobin (g/dl) | ||||||
| months 1 to 3 | 11.4 (1.2) | 10.4 (1.4) | 11.1 (1.2) | 11.4 (1.0) | 11.6 (1.0) | 12.0 (0.8) |
| months 4 to 6 | 10.0 (0.6) | 9.7 (0.8) | 10.0 (0.7) | 10.0 (0.6) | 10.0 (0.6) | 10.0 (0.5) |
| Month-3 mean EPO dose (units) | 6996 (6102) | 13,503 (8405) | 8928 (6187) | 6586 (4576) | 5545 (4164) | 3230 (2892) |
| Any hospitalization | ||||||
| months 1 to 3 | 32.1 | 45.2 | 34.9 | 29.9 | 15.2 | 26.1 |
| months 4 to 6 | 45.8 | 51.6 | 47.6 | 44.2 | 45.0 | 43.2 |
a
Values in parentheses indicate SD.
b
Geometric mean.
TSAT, transferrin saturation; URR, urea reduction ratio.